Zoetis Inc.
Zoetis Reports Strong Q1 2024 Results and Updates Full-Year Guidance
Summary
Zoetis Inc. reported a 10% increase in Q1 2024 revenue to $2.2 billion and a 9% rise in net income to $599 million. Operational revenue grew by 12%, and adjusted net income increased by 15%. The company updated its full-year 2024 guidance with an expected revenue range of $9.050 - $9.200 billion and adjusted net income between $2.620 - $2.670 billion. Segment performance showed significant growth in the U.S. and continued strength internationally.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement